TCRX

Tscan Therapeutics Inc

Apr 08 • 04:00PM ET

1.06

-0.01 -0.93 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP ALLO NTLA FATE BLUE EDIT CLLS PGEN ADAP

Index	-	P/E	-	EPS (ttm)	-1.00	Insider Own	16.28%	Shs Outstand	52.63M	Perf Week	4.95%
Market Cap	60.32M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	1.78%	Shs Float	47.64M	Perf Month	-14.52%
Enterprise Value	2.05M	PEG	-	EPS next Q	-0.20	Inst Own	51.79%	Short Float	3.97%	Perf Quarter	-7.02%
Income	-129.77M	P/S	5.84	EPS this Y	6.87%	Inst Trans	-6.45%	Short Ratio	3.37	Perf Half Y	-48.29%
Sales	10.32M	P/B	0.49	EPS next Y	6.84%	ROA	-43.26%	Short Interest	1.89M	Perf YTD	6.00%
Book/sh	2.16	P/C	0.40	EPS next 5Y	6.88%	ROE	-71.28%	52W High	2.57 -58.75%	Perf Year	-10.17%
Cash/sh	2.68	P/FCF	-	EPS past 3/5Y	28.66% 2.08%	ROIC	-61.77%	52W Low	0.88 20.13%	Perf 3Y	-51.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.63% 56.92%	Gross Margin	72.25%	Volatility	7.07% 6.52%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.20	EPS Y/Y TTM	12.67%	Oper. Margin	-1315.38%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.41	Sales Y/Y TTM	266.65%	Profit Margin	-1256.81%	RSI (14)	51.82	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.41	EPS Q/Q	40.34%	SMA20	1.34%	Beta	1.02	Target Price	6.00
Payout	-	Debt/Eq	0.76	Sales Q/Q	286.02%	SMA50	1.74%	Rel Volume	1.73	Prev Close	1.07
Employees	142	LT Debt/Eq	0.71	Earnings	Mar 04 BMO	SMA200	-25.71%	Avg Volume	561.53K	Price	1.06
IPO	Jul 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	33.41% 5.40%	Trades		Volume	962,170	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

Apr-08-26 07:00AM	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-26 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 (GlobeNewswire)
Feb-25-26 12:15PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.71%
07:00AM	Loading…
07:00AM	TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-11-26 07:25AM	Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +13.14%
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-06-25 05:30PM	TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +6.86%
Dec-03-25 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities (GlobeNewswire) +7.12%
Nov-12-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
05:10PM	Loading…
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +11.93%
Nov-06-25 09:15AM	Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Nov-03-25 06:30AM	TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 (GlobeNewswire) -36.08%
Oct-30-25 09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart) +11.21%
Sep-17-25 07:00AM	TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 (GlobeNewswire) -6.98%
Sep-03-25 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.86%
Aug-12-25 03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 08:25AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
May-28-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
09:10AM	Loading…
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-25 04:53PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting (GlobeNewswire)
Mar-31-25 07:00AM	TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 07:00AM	TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access (GlobeNewswire)
Mar-05-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.76%
Feb-18-25 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jan-10-25 09:35AM	Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks (Zacks)
Dec-26-24 07:00AM	TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium (GlobeNewswire) +6.87%
Dec-23-24 07:00AM	TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank (GlobeNewswire)
Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56% +10.46%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Dec 19 '25	Buy	0.90	80,069	71,974	7,937,416	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 22 '25	Buy	0.90	75,500	67,950	8,012,916	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 23 '25	Buy	0.90	6,232	5,602	8,019,148	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	May 19 '25	Buy	1.20	1,388,794	1,666,553	6,746,141	May 21 04:49 PM
Lynx1 Capital Management LP	10% Owner	May 20 '25	Buy	1.20	1,200,000	1,440,000	7,946,141	May 21 04:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your Finviz experience